P21

P21 is a synthetic, palmitoyl peptide derived from CNTF signaling and studied for hippocampal neurogenesis; the small community around it runs the peptide for cognitive enhancement and memory. The captured community corpus totals two reports—both positive, both low-confidence—which affirm the cognitive use case but offer no dose, timing, or cycling details. The off-label evidence base is thinner than online discussion implies; exploratory indications in the literature carry virtually no posted human results, so there is very little solid ground beyond those two anecdotal reports.

P21

Research Evidence

Evidence shape

P21 has limited clinical evidence: two Phase 1 trials in acute myeloid leukemia and idiopathic thrombocytopenic purpura enrolled sixteen subjects combined, with blinded results posted for only one. Across three mapped indications and two distinct sponsors, the other completed trial has no posted results and the third indication is animal-only preclinical work. The long tail is single-trial exploration that has not been replicated at scale.

Depthhow much
2 registered trials
2 completed · 1 with posted results · combined n=16
Breadthhow many areas
3 indications mapped
2 thin / exploratory · 1 animal-only · 2 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 1
1 blinded with results · 2 distinct sponsors
Breadth and depth18 rows captured
Human
direct clinical signal
2
Animal
translational support
4
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

1
US
50 mg
$64.95
$1.3/mg
2
UK
5 mg
$30.85
$6.17/mg
3
--
10 mg
$79.90
$7.99/mg
4
US
5 mg
$50.00
$10/mg
5
--
10 mg
$119.00
$11.9/mg
6
US
5 mg
$61.00
$12.2/mg

price offers can be sorted by column

1-6 of 10

Dosing & Protocol

How P21 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 2
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

2 completed trials identified; trial dosing not reliably extracted from registry data.

2 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 2
Typical dose
No quantified dose captured for this tier.
Frequency
unspecified
Route
subQ
Cycle
unspecified

Community reports for P21 are limited, with 2 reports specifically mentioning cognitive enhancement and memory benefits, all showing positive outcomes. Specific dosing insights are absent in community discussions.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for P21, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.